Which groups benefited most from an ECHELON-1 approach?
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL. Interview by Esther Drain.
Professor Anas Younes (MSKCC, New York), Professor John Radford (Manchester) and Dr Graham Collins (Oxford). Interviews by Esther Drain. Once again ASH provided much food for thought and above leading experts discuss their… read more.
Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.
Professor Stephen Ansell (Mayo Clinic, USA) speaks about harnessing the power of immunotherapy in Non Hodgkin’s Lymphoma.
by Maria Dalby Effective treatment options for perianal fistulas constitute a major unmet need in Crohn’sdisease (CD). New interventions included a knot-free silicon drain to replace conventional setons, and a circular blade… read more.
ESCP 2017 delegates give their highlights, plus a report on the ESCP/ECCO symposium on ulcerative colitis and a focus on quality of life for patients with perianal Crohn’s disease.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a… read more.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) In an overview of the immunological rationale for, and clinical application of adipose-derived mesenchymal stem cell (MSC) therapies, Dr… read more.
Professor Peter Johnson (Southampton, UK) tells us what’s new with response-adapted therapy and what are the benefits to patients.
A drug used to prevent epileptic seizures, levetiracetam, shows positive impact on the brain activity of patients with mild Alzheimer’s disease, researches reported on June 23, 2017 in… read more.
Researchers report that treatment of at-risk pregnant women with low-dose aspirin (150 mg) resulted in a significant reduction in pre-term preeclampsia.
Men who have received initial treatment for prostate cancer with abiraterone added to hormone therapy achieved a survival rate 37 per cent higher than those not treated with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.